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Solid organ transplantation is accepted as a stan-
dard lifesaving therapy for end-stage organ fail-
ure in children. This article reviews trends in pe-
diatric transplantation from 1996 to 2005 using
OPTN data analyzed by the Scientific Registry of
Transplant Recipients. Over this period, children have
contributed significantly to the donor pool, and al-
though the number of pediatric donors has fallen from
1062 to 900, this still accounts for 12% of all deceased
donors. In 2005, 2% of 89 884 candidates listed for
transplantation were less than 18 years old; in 2005,
1955 children, or 7% of 28 105 recipients, received a
transplant. Improvement in waiting list mortality is
documented for most organs, but pretransplant mor-
tality, especially among the youngest children, re-
mains a concern. Posttransplant survival for both pa-
tients and allografts similarly has shown improvement
throughout the period; in most cases, survival is as
good as or better than that seen in adults. Examination
of immunosuppressive practices shows an increasing
tendency across organs toward tacrolimus-based reg-
imens. In addition, use of induction immunotherapy
in the form of anti-lymphocyte antibody preparations,
especially the interleukin-2 receptor antagonists, has
increased steadily. Despite documented advances in
care and outcomes for children undergoing transplan-
tation, several considerations remain that require at-
tention as we attempt to optimize transplant manage-
ment.
Key words: Allocation, immunosuppression, living
donors, OPTN, pediatric transplantation, SRTR, sur-
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Introduction
This article is the fifth in a series of annual reviews pre-
senting data and analysis from the Scientific Registry of
Transplant Recipients (SRTR) regarding pediatric solid or-
gan transplantation in the Unites States (1–4). It will present
updated trends, discussion of analyses presented during
the year by the SRTR to the committees of the Organ Pro-
curement and Transplantation Network (OPTN) and discus-
sion of important issues regarding pediatric organ trans-
plantation raised throughout the past year. Unless other-
wise stated, the statistics in this article are drawn from the
reference tables of the 2006 OPTN/SRTR Annual Report.
In this article, pediatric patients are defined as candidates,
recipients or donors aged 17 years or less. Throughout this
article, data for both graft and patient survival are reported
as unadjusted survival unless otherwise stated (adjusted
patient and graft survival are available in the reference
tables). Short-term survival (3-month and 1-year) reflects
outcomes for transplants performed in 2003 and 2004; 3-
year survival reflects transplants done from 2001 to 2004;
5-year survival reports on transplants performed from 1999
to 2004. Details on the methods of analysis employed may
be found in the reference tables themselves or in the tech-
nical notes of the 2006 OTPN/SRTR Annual Report, both
available online at http://www.ustransplant.org.
This article, unlike the organ-specific articles in this re-
port, discusses data pertaining to all types of solid or-
gan transplantation in a specific subgroup of candidates,
namely children. The considerations particular to pediatric
populations have been discussed in the previous SRTR an-
nual reports (1–4), and, in recognition of these issues, the
transplant community has generally been willing to pro-
vide special consideration for children in terms of allocation
policy.
The progress made in pediatric organ transplantation over
the last 20 or more years has been well documented in
the literature (5–9). However, because of the small size
of most pediatric programs, cumulative multicenter data
covering all recipients and donors in the United States
are of special importance. These data, collected by the
OPTN and used for complex analysis and modeling by the
SRTR, provide important information for use by the OPTN
Pediatric and organ-specific committees, guiding both
discussion and modification of organ allocation and out-
comes assessment. In addition, the pediatric community
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has developed several other national and international
multi-center collaborations, including the North American
Pediatric Renal Transplant Cooperative Study (NAPRTCS)
and the Studies of Pediatric Liver Transplant (SPLIT), as
sources for further in-depth analyses.
Pediatric organ donors
Pediatric donation has declined somewhat in the past
10 years, both in number (from 1062 donors in 1996 to
900 in 2005) and in the percentage of total donors (from
20% in 1996 to 12% in 2005). The distribution of pedi-
atric donor ages has remained consistent, with close to
60% of pediatric donors aged between 11 and 17 years.
Among deceased kidney donors, the number and per-
centage of pediatric donors declined between 1996 and
2005, from 978 (19%) to 799 (12%). The age distribu-
tion of pediatric kidney donors has remained consistent.
The number of pediatric pancreas donors has increased
more slowly than the number of adults donating pancre-
ata; the number of pediatric donors grew from 295 to
391, while the percentage of pediatric donors declined
from 23% to 19%. The age distribution has fluctuated, but
the largest group of pediatric pancreas donors has been
among ages 11–17 years (80–91% each year). While the
total number of liver donors has increased over the past
10 years, the number of pediatric liver donors has de-
creased, from 946 (21%) to 815 (12%). As with other or-
gans, donors aged 11–17 years make up the largest frac-
tion of pediatric liver donors in 2005, at 58%. The num-
ber of pediatric intestine donors has increased from 34
to 133, but no consistent trend in percentage has been
observed. The number of pediatric heart donors has de-
clined faster than the number of adult heart donors, from
620 (25%) to 455 (20%). The absolute number of pedi-
atric lung donors has not changed substantially, but the
percentage of pediatric donors has declined from 24%
to 16%.
The number of organs that become available from pediatric
donation after cardiac death (DCD) has been increasing.
Beginning next year, all hospitals will need to demonstrate
that they are establishing policies and procedures for han-
dling DCD.
Waiting list
The total number of pediatric candidates on the waiting list
increased steadily, from 1621 in 1996 to a peak of 2344
in 2001. The total has since leveled, with 2181 candidates
(both active and inactive) in 2005 (Figure 1). Distribution by
age of pediatric candidates on the waiting list has remained
consistent, with 6% aged less than 1 year, 27% 1–5 years,
20% 6–10 years and 47% 11–17 years at the end of 2005.
The overall percentage of the waiting list made up of pedi-
atric candidates has declined somewhat from 3% in 1996
to 2% in 2005. Changes in the pediatric waiting list by or-
gan type are illustrated in Figure 2.
Source: 2006 OPTN/SRTR Annual Report, Table 1.4.
Figure 1: Pediatric transplant waiting list (active and inactive)
at year-end for all organs, by age, 1996–2005.
Transplantation and survival
Over the 10-year period, the number of pediatric recipients
of any organ grew 23% (from 1594 to 1955), in contrast to
the 44% increase in the number of adult recipients (from
18 153 to 26 150). The largest increase, 30%, occurred in
the largest group, recipients 11–17 years old (661 in 1996
and 861 in 2005). The remaining pediatric groups expe-
rienced increases of smaller proportion: recipients 6–10
years old increased 14% to 308, recipients 1–5 years old
18% to 494 and recipients less than 1-year-old 19% to
292. As with the waiting list, the age distribution among
transplant recipients has remained stable, with 15% under
1 year, 25% 1–5 years, 16% 6–10 years and 44% 11–17
years in 2005. The proportion of pediatric patients among
recipients has declined, from 8% in 1996 to 7% in 2005.
Kidney Transplantation
It has become axiomatic that kidney transplantation is the
optimal treatment for children with end-stage renal disease
Source: 2006 OPTN/SRTR Annual Report, Tables 5.1a, 9.1a, 10.1a,
11.1a, and 12.1a.
Figure 2: Distribution of active pediatric waiting list candi-
dates at year-end, by organ, 1996–2005.
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Source: NAPRTCS 2006 Annual Report.
Figure 3: Pediatric patient survival 36 months after kidney
transplantation versus dialysis.
(ESRD), and approximately two-thirds of pediatric patients
with ESRD will undergo kidney transplantation (10). Numer-
ous studies document the improvements in medical out-
comes, cognitive function, social adjustment, sexual mat-
uration and quality of life that accompany kidney transplan-
tation (10).
Perhaps most importantly, survival in pediatric patients
with kidney transplants clearly exceeds that seen with dial-
ysis. Data from the 2006 NAPRTCS show that at every age,
patient survival at 3 years with either living donor or de-
ceased donor transplantation is markedly superior to that
seen in dialysis patients (Figure 3) (11). Even this may un-
derstate the value and importance of kidney transplantation
in pediatric patients. Recent data from the United States
Renal Data System (12) show that at all ages, the years of
life expectancy are greater in transplant patients compared
with those receiving dialysis, but improvement is clearly
greatest in children and adolescents (Figure 4). In children
aged 0–14 years, there was an improvement of 30 years;
overall, there was an expected calculated remaining life-
time of 50 years for transplant recipients. In patients 15–19
Source: USRDS 2005 Annual Data Report, Table 6b.
Figure 4: Expected remaining lifetimes (years) of dialysis and
transplant patients with ESRD, by age.
Source: 2006 OPTN/SRTR Annual Report, Table 5.2.
Figure 5: Median time to transplant for new kidney transplant
waiting list registrants, by age, 1996–2005.
years old, the improvement in life expectancy for transplant
recipients over dialysis patients is approximately 25 years,
and the overall calculated remaining lifetime expectancy is
40 years.
Waiting list
The kidney transplant community and the OPTN have been
committed to expediting kidney transplantation for children
and adolescents. Within the allocation framework of the
OPTN, a number of algorithms have been used in attempts
to transplant pediatric patients as promptly as feasible with
organs that are optimal, both physiologically and immuno-
logically. Until recently, the generally agreed-upon underly-
ing principle regarding deceased donor allocation has been
to try to transplant children from 0 to 6 years old within
6 months, children from 7 to 12 years within 12 months
and patients 12–18 years within 18 months. Over the past
10 years, these efforts have been moderately successful
(Figure 5). Since 1998, the youngest children have experi-
enced the shortest median waiting time. Moreover, since
2003, pediatric patients aged 6–10 years and 11–17 years
have had dramatic decreases in their median waiting time.
Source: 2006 OPTN/SRTR Annual Report, Table 5.1a.
Figure 6: Active pediatric kidney patients on the waiting list
at year-end, 1996–2005.
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Source: 2006 OPTN/ SRTR Annual Report, Tables 5.4a and 5.4c.
Figure 7: Pediatric kidney transplant recipients, by donor
type, 1996–2005.
In 2005, the median waiting time for all pediatric groups
was less than 300 days. This compares favorably with the
latest data on median waiting time in adults, which over
the past 10 years was never less than 920 days in any age
group.
Over the past 10 years, the size of the active pediatric wait-
ing list has consistently remained in the range of 500–650
(Figure 6). Parenthetically, the adult waiting list has grown
from 28 241 in 1996 to 45 853 in 2005. If pediatric patient
waiting time is decreasing as the size of the waiting list re-
mains essentially stable, then it seems logical to expect an
increase in the number of pediatric kidney transplants per-
formed over this time. There appears to be a trend toward
an increasing total number of transplants to pediatric recip-
ients since 2000 (Figure 7), mostly due to an increase in
deceased donor transplants. Kidney transplants performed
as part of kidney-liver transplantation have consistently re-
mained at approximately 2–5% of the total number of kid-
ney transplants (Figure 8) (SRTR analysis, May 2006).
Transplantation and survival
There has been some increase in the number of living
donor transplants over this time. However, the number of
Source: 2006 OPTN/SRTR Annual Report, Table 5.4a and SRTR
Analysis, May 2006.
Figure 8: Percentage kidney/liver transplants among de-
ceased donor kidney transplants to pediatric recipients, 1996–
2005.
Source: 2006 OPTN/SRTR Annual Report, Table 5.4a.
Figure 9: Pediatric transplant recipients of non-ECD deceased
donor kidneys, by age, 1996–2005.
deceased donor transplants has increased markedly, from
278 in 2000 to 468 in 2005 . Historically, in pediatric ESRD
patients, the number of living donor transplants has con-
sistently exceeded the number of deceased donor trans-
plants; but 2005 was the first year in a decade that the
number of deceased donor transplants exceeded the num-
ber of living donor transplants (Figure 7). In contrast, the
number of deceased donor transplants to adults has con-
sistently exceeded the number of living donor transplants
to adults.
With regard to living donor transplants, the number for each
age group has remained essentially the same over the past
decade. However, there have been increases in the num-
ber of deceased donor transplants in all three pediatric pa-
tient age groups (Figure 9). The increases since 2000–2001
in the two younger age groups have been relatively mod-
est, but the increase in the number of patients aged 11–17
years has been quite dramatic. In 2005, 70% of pediatric
Source: 2006 OPTN/ SRTR Annual Report, Table 5.10a.
Figure 10: Unadjusted 3-month, 1-year, 3-year and 5-year
graft survival of deceased donor non-ECD kidney transplants,
by recipient age.
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Source: 2006 OPTN/SRTR Annual Report, Table 5.10c.
Figure 11: Unadjusted 3-month, 1-year, 3-year and 5-year
graft survival of living donor kidney transplants, by recipient
age.
kidney transplants were performed in the 11–17-year-old
group.
The traditional OPTN approach for expediting children’s ac-
cess to renal transplantation had been to give extra al-
location points to provide them greater priority. It was
hoped that these extra points would reflect the desire to
offer a reasonable balance between HLA matching and
expedited access. Recently, the SRTR, working with the
OPTN Kidney-Pancreas Committee, demonstrated that the
characteristic most associated with improved outcome in
deceased donor pediatric transplantation was donor age
between 5 and 35 years (13). Thus in 2005, the OPTN im-
plemented a pediatric kidney allocation policy under which
relative priority for kidneys from deceased donors less than
35 years old was assigned to recipients less than 18 years
old, after any zero mismatch transplants, recipients with a
PRA > 80, or candidates receiving a kidney with a nonrenal
organ (14). While some worry about the lower likelihood of
a highly matched kidney under such a policy, Gritsch et
al., using OPTN data, independently reported that, except
for zero mismatched allografts, the impact of HLA match-
ing in deceased donor pediatric kidney transplantation was
minor (15). The increase in pediatric transplant activity in
2005 (Figure 7) suggests that this policy may be having
the desired effect, but further analysis will be necessary to
confirm this.
Pediatric kidney allograft outcome is excellent, at least in
the short term. In all three age groups, results for deceased
donor transplants at 3 months and 1 year are as good as
those in any other age group (Figure 10). This statement
holds true for results at 3 and 5 years for patients aged 1–
5 years and 6–10 years. However, results in patients who
were transplanted as adolescents show a greater fall off
over 3–5 years. Indeed, at 5 years after transplantation,
those patients who were transplanted as adolescents had
the poorest allograft outcome of any age group except for
recipients aged 65 and older. A similar pattern, although
less pronounced, could be observed in recipients of living
donor transplants (Figure 11). These are sobering statis-
tics, and, while registry data cannot be used to establish
causation, a large body of work suggests that medication
nonadherence is likely a major contributor (16,17). While
behavioral issues are often offered as the primary factor
contributing to nonadherence, another potential variable
is the loss of medical insurance that some adolescents
may face as they transition to adulthood. The impact of
this upon medication nonadherence is unknown; gathering
more information related to insurance coverage is impor-
tant to fully understand this issue.
It has been observed by Watson, among others, that the
transition from adolescence to young adulthood is a tur-
bulent and potentially hazardous time for kidney transplant
recipients (18). Watson described a small but potentially
meaningful experience in England, where it is relatively
easy to follow the outcome of pediatric transplant patients
into adulthood. He noted that within 15 months of transi-
tioning from pediatric nephrology care to internal medicine,
a shocking 30% of patients had lost their allografts. This
phenomenon has become a growing concern for many
in pediatric transplantation. However, it is difficult to cap-
ture large-scale data on this issue, since pediatric registries
such as NAPRTCS cease collecting data when pediatric
patients reach adulthood. Because the SRTR can follow
outcomes after patients reach 18 years, this database can
be a valuable tool in the evaluation of this issue. Attempt-
ing to define the problem, Magee et al. have suggested
that much of the risk of graft loss in this population begins
early in adolescence rather than being solely associated
with turning 18 years of age (19).
Immunosuppression
Multiple reports have described a year-by-year improve-
ment in pediatric renal graft outcome (10). Graft survival
has consistently improved, and the number of acute rejec-
tion episodes has progressively decreased. There are mul-
tiple reasons for these improvements, but changes and im-
provements in immunosuppression have certainly played
an important part. Over the past 10 years, there have been
marked changes in the use of immunosuppressive agents
in pediatric patients (SRTR analysis, May 2006) (Figure 12).
The use of cyclosporine has fallen from almost 80% in
1996 to less than 15% in 2005. In parallel with this, the
use of tacrolimus (Prograf®, Astellas Pharma U.S., Deer-
field, IL) rose from less than 15% in 1996 to approximately
80% in 2005. In large part, this switch was engendered
by the adverse cosmetic effects of cyclosporine in pedi-
atric patients. Anti-metabolites, increasingly in the form
of mycophenolate (Cellcept®, Roche, Nutley, NJ; Myfor-
tic®, Novartis, East Hanover, NJ), were used consistently
over the past decade in approximately 80% of pediatric pa-
tients. Over the past 2 years, there has been a decrease
in the use of corticosteroids beginning at discharge from
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Source: SRTR Analysis, May 2006.
Figure 12: Immunosuppression use for maintenance of pe-
diatric recipients with kidney transplants prior to discharge,
1996–2005.
transplant surgery hospitalization. The side effects of
steroids weigh heavily upon pediatric ESRD patients, and
so the desire to avoid steroids is understandable. A multi-
center, randomized controlled trial of steroid-free immuno-
suppression has reached full enrollment, and the results
are eagerly anticipated.
Figure 13 shows the immunosuppressive combinations
that have been initiated in pediatric renal transplant recipi-
ents over the past 10 years (SRTR analysis, May 2006). In
2005, the most popular combination, used in almost 60%
of patients, was tacrolimus, corticosteroids and mycophe-
nolate mofetil (MMF) or mycophenolate sodium. The sec-
ond most popular regimen in 2005 was the steroid-free
combination of tacrolimus and mycophenolate.
The role of biologic agents for induction has been con-
troversial in pediatric kidney transplant recipients. How-
ever, use of at least one biologic agent is increasing year
by year; Figure 14 shows a constant decrement in pedi-
atric patients with no induction drugs recorded. As a class,
the humanized/chimeric anti-CD 25 monoclonal antibod-
Source: SRTR Analysis, May 2006.
Figure 13: Immunosuppression combinations for mainte-
nance for pediatric recipients with kidney transplants prior
to discharge, 1996–2005.
Source: SRTR Analysis, May 2006.
Figure 14: Immunosuppression use for induction for pediatric
recipients with kidney transplants, 1996–2005.
ies are most used. However, in the last 2 years, rabbit
anti-thymocyte globulin (Thymoglobulin®, SangStat Med-
ical Corp., Fremont, CA, 1999) was the induction agent of
choice (SRTR analysis, May 2006).
Liver Transplantation
In the United States, between 1996 and 2005, 5675 chil-
dren and adolescents received liver transplants. No ma-
jor technical innovations in liver transplantation occurred
during this period, but undoubtedly refinements in surgi-
cal technique and improvements in pre- and post-operative
care have contributed to continually improving outcomes
in terms of survival for both patients and allografts. We are
constantly reminded that children differ from adult trans-
plant recipients in terms of size, etiology of organ failure
and pharmacokinetics; but in fact these differences also
exist within the pediatric population. Congenital causes
of liver disease predominate in infants and young chil-
dren, and an increasing incidence of acquired cholestatic
disease appears in older children and adolescents. The
peak incidence of liver transplantation in childhood oc-
curs during the first year, dropping sharply in subsequent
age groups. Developmental outcomes are of greatest con-
cern in the youngest candidates, but growth and puber-
tal development remain important considerations until fi-
nal adult height is achieved. Currently, allocation policy
for livers is based on 90-day mortality risk, but there is
increasing concern that this may not address the poten-
tial for timely liver transplants to avoid irreversible morbid-
ity such as short stature, impaired puberty and cognitive
and emotional development issues. These questions of
long-term quality outcomes cannot be answered by OPTN
data as currently collected, but such data are nonetheless
of crucial importance when determining optimal applica-
tion of liver transplantation for pediatric populations. Well-
designed, prospective, multicenter collaborative data sets,
such as those of the SPLIT registry, will be required to
guide understanding on these issues.
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Source: SRTR Analysis, May 2006.
Figure 15: Reported pediatric liver only (no intestine) waiting
list deaths and annual death rates per 1000 patient-years at
risk, 1996–2005.
Waiting list
The number of pediatric patients on the liver waiting list
grew steadily, from 498 in 1996 to a peak of 703 in 2001;
it has since declined to 462 in 2005. The sudden decline in
new listings of pediatric patients after 2001 clearly reflects
the introduction of the Pediatric End-stage Liver Disease
(PELD) and Model for End-stage Liver Disease (MELD)
scoring systems, which removed the need to list a patient
early in order to accrue waiting time. In addition, objec-
tifying waiting list mortality may have enabled clinicians
to make sounder judgments on when to list a child with
chronic liver disease. Of the children active on the waiting
list at the end of 2005, 73 were less than 1 year of age,
170 were 1–5 years, 83 were 6–10 years and 136 were
11 years or older. Though the number of pediatric patients
on the liver waiting list in 2005 is nearly equal to the num-
ber in 1996, pediatric candidates now make up a much
smaller proportion of the liver waiting list (4% compared
with 8% in 1996) because of the large growth in the num-
ber of adults active on the liver waiting list, which more
than doubled from 5782 in 1996 to 12 360 in 2005.
Annual death rates per 1000 patient-years at risk for pe-
diatric candidates on the waiting list for liver only (no in-
testine) have been variable but displayed a downward
trend between 1996 and 2004. However, death rates were
higher in 2005 than 2004, at 95 for 1–5-year-olds, 41 for
6–10-year-olds and 58 for 11–17-year-olds (SRTR analysis,
May 2006) (Figure 15). Death rates for children less than
1 year old were too variable to distinguish any trend; but,
as previously described, this group has the highest death
rate while awaiting liver transplantation. Figure 15 demon-
strates that this high death rate is not entirely accounted
for by infants awaiting combined liver and intestine trans-
plantation. As can be seen, the waiting list mortality rate
for infants less than 1 year is between four and eight times
that of older children. If we wish to change this high rate,
several potential contributing factors will need to be exam-
ined to determine causes and possible solutions: (1) etiol-
ogy of liver failure; (2) timing of referral for transplantation;
Source: 2006 OPTN/SRTR Annual Report, Tables 9.4a and 9.4b.
Figure 16: Pediatric recipients of deceased and living donor
liver transplants, 1996–2005.
(3) appropriate hepatological and intensive care; (4) organ
availability; (5) center size and volume and (6) availability of
the full range of technical innovations at the listing center,
including segmental and living-related liver transplantation.
Overall, 101 children died waiting for liver transplantation in
2005, of which 45 were also listed for an intestinal allograft
(SRTR analysis, May 2006).
Concerns have been raised about the ability of the PELD
score to reliably prioritize children for liver transplantation
(20,21). Also, the correlation with MELD scores may be
imprecise, making it difficult for children to compete with
adult candidates for organs (20,21). Both of these factors
have been felt to disadvantage certain candidates in terms
of timely access to a liver allograft. The perceived lack of
a competitive score has resulted in an excessive number
of exception scores being requested from and granted by
regional review boards. The use of exception scores, and
particularly Status 1 by exception, varied from region to re-
gion, but it is probable that this practice undermined the
severity scoring systems and further limited their useful-
ness (22–24). Recent changes in liver allocation policy have
attempted to address these issues. The changes to Sta-
tus 1 limit listing at this most acute status to those who
fulfill strict criteria. For a patient outside criteria there is
no longer an option to be listed at Status 1 by exception.
To gain additional advantage on the waiting list requires
prospective submission to local regional review boards for
additional PELD or MELD points. In an attempt to guide the
regional review boards in granting exception points con-
sistently across the country, a subcommittee of the Liver
and Intestine Committee has produced guidelines for sev-
eral of the more common conditions for which exception
scores are requested (23–25). Attempts to create a na-
tional review board to achieve patent consistency from re-
gion to region have yet to succeed. Although it is too soon
to be certain, preliminary analyses of deaths on the wait-
ing list and pediatric transplants, presented to the OPTN
Pediatric Committee, suggest that although the number of
patients transplanted at Status 1 has inevitably fallen, there
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Source: 2006 OPTN/ SRTR Annual Report, Tables 9.7a.
Figure 17: Death rates for pediatric recipients during first year
after deceased donor liver transplantation, 1996–2004.
has been no effect on overall pediatric transplant numbers
or on pre-transplant mortality rates.
Transplantation and survival
Figure 16 shows that the total number of pediatric liver
transplants per year has been stable in the range of 500–
600 procedures annually over the whole period. The num-
ber of deceased donor liver transplants to pediatric can-
didates has ranged from 444 to 529 annually over the
10-year period, ending with 509 recipients in 2005. Liv-
ing donor recipients peaked in the year 2000 at 118 but
diminished to 57 in 2005. The reasons for this decline may
be related to the introduction of MELD/PELD, which has
enabled sicker patients greater access to deceased donor
organs. Did fewer ‘not-so-sick’ listings, as is suggested by
the reduction in the liver waiting list following the introduc-
tion of MELD/PELD, allow those in need, but with limited
waiting time, access to deceased donor organs? The ef-
fect of highly publicized donor deaths in adult-to-adult living
donor liver transplantation cannot be discounted, possibly
making potential donors or their physicians and surgeons
more reluctant to embark on living donor transplantation.
As with death rates on the waiting list, death rates in the
first year after deceased donor transplantation have been
quite variable over the decade but appear to trend down-
ward, ending at 60 deaths per 1000 patient-years at risk
for infants less than 1 year, 164 for 1–5-year-olds, 112 for
6–10-year-olds and 60 for 11–17-year-olds (Figure 17).
Long-term survival is known to be better in children than
in adult liver transplant recipients, presumably because
of the lack of comorbidities in children. Children are also
less likely than adults to have a primary diagnosis asso-
ciated with significant risk of recurrence leading to graft
failure. In 2004, the death rates for every pediatric age
group were lower than that for adults aged 18–34 years,
even during the first year after deceased donor liver
transplantation.
Source: SRTR Analysis, May 2006.
Figure 18: Immunosuppression use for maintenance of pedi-
atric recipients with liver transplants prior to discharge, 1996–
2005.
Among liver recipients under 6 years, graft survival at
1 year was higher for those who received living donor
livers than for recipients of deceased donor livers (for
less than 1 year: 90% vs. 84%; for 1–5 years: 90% vs.
80%). The numbers of older children who have received
a living donor liver allograft are too small for conclusions
to be made about graft and patient survival among the
6–10 and 11–17 year age groups. Unadjusted graft sur-
vival among recipients of deceased donor transplants at
1 year was higher for these age groups (86% for 6–10-year-
olds, 88% for 11–17-year-olds). Among deceased donor
recipients, patient survival at 1 year was best for 11–
17-year-olds at 94% and worst for 1–5-year-olds at 90%.
Given that the number of liver transplants to adults has
increased while the number to pediatric candidates has
remained steady, it is not surprising that though the num-
ber of pediatric recipients (<18 years at transplant) alive
with a functioning liver increased 67%, from 2554 in 1996
to 4267 in 2004, their proportion decreased, from 15%
to 13%.
Immunosuppression
Trends in pediatric maintenance immunosuppression over
the last 10 years can be glimpsed from Figure 18 (SRTR
analysis, May 2006). Although most pediatric liver trans-
plantation (∼80%) is done without induction immunosup-
pression, since 1998 the use of the interleukin-2 recep-
tor (IL-2R) inhibitors basiliximab (Simulect®, Novartis, East
Hanover, NJ, 2000) and daclizumab (Zenapax®, Roche, Nut-
ley, NJ, 1999) in particular has increased (SRTR analy-
sis, May 2006). The use of cytolytic anti-lymphocyte an-
tibody preparations has fluctuated in the 5–10% range,
but the preparation chosen has clearly switched from
mostly muromonab-CD3 (OKT3®, Orthobiotech, Bridge-
water, NJ) or horse anti-thymocyte globulin (ATGAM®,
Pharmacia & Upjohn, Kalamazoo, MI) to predominantly
rabbit anti-thymocyte globulin, with a few cases using
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alemtuzumab (Campath-1H®, ILEX Pharmaceuticals, San
Antonio, TX). In the last 5 years, around 90% of pedi-
atric liver transplant recipients received tacrolimus-based
maintenance immunosuppression therapy; cyclosporine
use has steadily decreased, from 22% of patients in 1999
to only 4% in 2005. Although steroid-free protocols are
frequently discussed, 84% of pediatric liver transplant
recipients were discharged on maintenance corticos-
teroids in 2005.
Recent changes in liver allocation policy
Last year saw the introduction of three new allocation pol-
icy (14) changes: Share 15 (OPTN Policy 3.6), regional shar-
ing of pediatric donors (OPTN Policy 3.6) and the new Sta-
tus 1 criteria (OPTN Policy 3.6.4.2). In addition, changes
in allocation policy regarding multi-organ transplants that
include liver were also adopted.
Share 15 (OPTN Policy 3.6): It was noted that adults on
the liver waiting list have a clear survival advantage at 1 year
with transplantation if their MELD score was greater than
or equal to 18 and a similar risk of death in the first year with
or without transplantation between MELD scores of 15 and
18 (26). It was therefore decided to offer livers for trans-
plantation in adults preferentially to recipients locally, then
regionally to candidates with MELD scores greater than 15
before offering livers to candidates with scores less than
15. Because there are usually a considerably larger number
of adults with high MELD scores awaiting transplantation
than pediatric candidates in all regions at any given time,
it was feared that such a policy change would lead to a re-
duction in the number of children transplanted. To attempt
to compensate for this policy change, regional sharing of
pediatric donors was introduced contemporaneously with
Share 15.
Regional sharing of pediatric donor organs (OPTN Pol-
icy 3.6): To protect pediatric recipients from effects of
Share 15 and in an attempt to increase the use of pedi-
atric organs in pediatric recipients, allocation of livers from
deceased pediatric donors was adjusted. The aim was to
direct such organs to children awaiting liver transplantation.
An early analysis presented recently to the OPTN Pediatric
Committee (using only 4 months of data) suggests that fol-
lowing policy implementation there were more transplants
performed in recipients aged 0–11 years from donors aged
0–17 years but fewer in the 12–17-year age range. A slightly
smaller proportion of pediatric donor livers went to adult
recipients, but the majority (54%) of pediatric organs still
went to adult recipients. Also of note, more split liver trans-
plants were performed on younger recipients from donors
aged less than 18 years, thus making the right side of the
liver available for an adult candidate. Caution needs to be
applied to the interpretation of this analysis, given the small
numbers involved.
This does raise the concern that the policy adjustment is
possibly shifting organs away from adolescents to younger
children, rather than securing pediatric organs for all chil-
dren listed. The present allocation protocol offers pedi-
atric organs to 0–11-year-old patients (i.e. those with PELD
scores) before offering them to local adolescents. How-
ever, prior to extending offers to regional adolescents, the
list is run for local adults and, in this sense, cuts short the
pediatric preference at a regional level. This may warrant
future committee examination.
New Status 1 criteria (OPTN Policy 3.6.4.2): The revised
Status 1 criteria were also introduced in 2005. The criteria
divide the most acute status into two subcatagories, 1A
and 1B, the latter classification applying only to children
with decompensated chronic liver disease. Strict criteria
apply to each of the categories, and patients who do not
fulfill the required criteria cannot be listed at Status 1 (A or
B) by exception.
Have such changes restricted children’s access to liver
transplantation? Or, have these policy adjustments simply
restructured priority for existing organs within the pedi-
atric population? The answer depends on whether Status
1 by exception candidates were getting organs from the
adult pool of deceased donors or whether such candidates
were drawing from the existing pediatric donor pool. It is
too soon to be certain, but the preliminary analysis, pre-
sented to the OPTN Pediatric Committee, of the 2 months
prior and subsequent to the implementation of this revision
and the previously discussed policy changes fails to show
any change in waiting list death rates for children aged
0–11 years and 12–17 years or adults between the two
periods.
A number of publications have voiced concern that the
present allocation system is not serving children well
(20,21,23), but pediatric pretransplant death rates have not
risen with the introduction of MELD/PELD nor with any of
the subsequent policy modifications. It is possible that the
candidates who die on the waiting list may have changed in
terms of the severity of diagnosis or geographical distribu-
tion from those who died waiting during the pre-MELD era.
The present system is predicated on the fact that there is a
mortality risk associated with each score. By definition, the
severity scoring system can only be validated by predicted
mortality rates approximating actual death rates; that is,
it is assumed that some children will die. This is hard to
accept when (1) there are more pediatric donors than the
relatively constant number of potential pediatric recipients
each year, and (2) the allocation system(s) have evolved to
most equitably deal with the tragic shortage of allografts
available for the ever growing numbers of adults with end-
stage liver disease.
New liver/intestine allocation changes: An SRTR analy-
sis of waiting list mortality comparing candidates of all ages
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listed for liver alone with those listed for a combined liver
and intestine transplant showed that the latter group had
higher mortality risk. There was no interaction between
PELD and the liver/intestine wait-listed candidates, indi-
cating a consistent difference in mortality across PELD
scores. The mortality risk among pediatric liver/intestine
candidates was 5.5 times higher than that among pediatric
liver candidates, which equates to 23 PELD points (95%
CI 18–28). For patients with a MELD score, the mortality
rate difference was smaller, and a clear interaction could be
seen between MELD and liver/intestine candidates. Thus,
as the MELD score increased, the mortality risk between
liver/intestine and liver-alone candidates diminished. At a
MELD score of 40, the waiting list mortality risk for the
two groups was essentially equal. In this regard, the cur-
rent provision of an additional 10% mortality risk for adult
patients on both lists simultaneously appears to work well
(SRTR analysis, April 2005).
With strict criteria in place for children with chronic liver
disease to upgrade to Status 1B, it has become obvious
that this category was essentially being denied to patients
with end-stage liver disease secondary to intestinal failure.
The need for positive pressure ventilation or a diminished
Glasgow Coma Score are contraindications for combined
liver and intestine transplantation in most cases—the pa-
tient being too sick to tolerate the procedure. However, por-
tal hypertensive bleeding is common in this patient group,
but the pattern of bleeding is different from those patients
with variceal bleeding and an intact gut. The current cri-
teria require blood replacement of at least 30 mL/kg in a
24-h period. In short bowel patients, the bleeding tends
to be persistent and resistant to medical and surgical in-
tervention. Although the bleeding is frequently sufficient
to require blood and blood product replacement on a daily
basis, rarely is it 30 mL/kg in a single day.
Current allocation policy allows, but does not direct, organ
procurement organizations (OPOs) to offer composite liver
and intestine allografts to patients listed for both organs ac-
cording to their position on the national intestine list, pro-
vided there is no Status 1 liver patient in the region. Feeling
uncomfortable with optional routes of organ allocation, the
OPTN OPO Committee requested more directive policy.
The current policy came into being originally because of
the massively high death rate of infants and young chil-
dren on the waiting list with end-stage liver disease and
intestinal failure. The high waiting list death rate is due in
large part to the limited number of composite grafts small
enough for these infants.
Clearly, an additional advantage is required for children
awaiting combined liver and intestine transplantation, and
unambiguous allocation policy is to be desired. Therefore,
the following suggestions have been submitted by the
OPTN Liver and Intestine Committee for public comment
and to the OPTN Board of Directors: (1) Children listed
simultaneously for liver and intestine transplant would
receive an additional 23 PELD/MELD points above their
calculated score. (2) For candidates on both the liver and in-
testine lists, gastrointestinal bleeding necessitating trans-
fusion of 10 mL/kg or greater in the preceding 24 h would
enable upgrading to Status 1B. (3) Small composite liver
and intestine allografts would be preferentially directed to
candidates needing both organs. The specific recommen-
dation is that all combined liver and intestine organs from
donors less than 11 years would be offered first to regional
Status 1 patients, then to regional pediatric liver candidates
with a PELD score of greater than 20, and then to pediatric
candidates at the national level listed for combined liver
and intestine transplantation and ranked according to their
PELD score.
While the preferential allocation of whole liver grafts to
these small liver and intestine recipients will likely improve
waiting list mortality in this very ill population, it is notewor-
thy that such a policy also likely will result in more techni-
cal variant grafts in the similarly sized liver-alone recipients.
Given that such technical variant grafts are associated with
a higher rate of graft loss (27,28), it will be vital to examine




The number of pediatric patients active on the intestine
waiting list more than doubled, from 53 in 1996 to 116
in 2005; however, the proportion of children on the list
remains stable, making up 77% of the total intestine can-
didates in 2005. The 25th percentile of time-to-transplant
has varied, with no consistent trends for pediatric patients
on the intestine waiting list, from 115 to 208 days for can-
didates less than 1 year (with a single outlier of 894 days
in 1997), 46 to 119 days for 1–5-year-olds, 15 to 183 days
for 6–10-year-olds and 4 to 226 days for 11–17-year-olds.
Median time-to-transplant is often not available for younger
children because fewer than 50% of these children have
been transplanted.
Annual death rates on the intestine waiting list have var-
ied extensively with the highest waiting list death rates of
any group of solid organ transplant candidates seen among
infants (<1 year old), most of whom are awaiting com-
bined liver and intestine transplantation. The more modest
death rates seen in the children over 5 years of age re-
flect that many more of the older children are listed for
intestine transplantation alone; that is, they do not have
liver failure. As was documented by Sweet et al. in last
year’s OPTN/SRTR Annual Report (4), 92% of deaths on
the intestine transplant waiting list are in patients with
chronic liver failure disease. The number of children dy-
ing on the intestine waiting list has shown no consistent
trend, but increased overall from 20 in 1996 to 47 in 2005.
Death rates for these children are unacceptably high, and
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2003 data includes patients transplanted 2000-2001; 2006 data in-
cludes patients transplanted 2003–2004.
Source: 2006 OPTN/SRTR Annual Report, Table 10.14 and 2004
OPTN/SRTR Annual Report, Table 10.11.
Figure 19: Unadjusted 1-year patient survival for intestine
transplants, by age, for 2003 and 2006.
attempts to address this problem have been discussed in
OPTN committees at length (see New Liver/Intestine Allo-
cation Changes section above).
Transplantation and survival
The number of intestine transplants in pediatric recipients
has grown, from 28 in 1996 to 94 in 2005. The incidence
of intestine transplants per 1 million population continues
to increase, and there is no suggestion that this is likely
to plateau in coming years. The increasing numbers of
patients considered suitable for intestine transplantation
most likely relate to a number of issues. Greater access
for patients with irreversible intestinal failure has occurred
because of both growth in established intestine transplant
programs and the development of new programs. There is
an increasing familiarity among referring physicians regard-
ing the possibilities of intestinal transplantation and recog-
nition that quality outcomes are possible. Finally, there also
may be a change in approach to abdominal catastrophes,
with surgeons, particularly those in neonatal practice, be-
coming more willing to undertake extensive intestinal re-
section now that a potential treatment option for the com-
plications of intestinal failure is available. There does not,
as yet, appear to be a relaxing of indications for intes-
tine transplantation, but this may, and probably will, oc-
cur as the survival figures for this procedure continue to
improve.
Improved short-term patient survival following intestine
transplantation can be seen by comparing 1-year survival
(Figure 19) from the most recent cohort analyzed in the
SRTR data set with that of the data presented in the 2003
OPTN/SRTR pediatric report (29).
Graft survival at 5 years for intestine recipients is 42% for
those less than 1 year, 48% for 1–5-year-olds, 60% for 6–
10-year-olds and 40% for 11–17-year-olds. Patient survival
2003 data includes patients transplanted 1996-1997; 2006 data in-
cludes patients transplanted 1999–2004.
Source: 2006 OPTN/SRTR Annual Report, Table 10.14 and 2004
OPTN/SRTR Annual Report, Table 10.11.
Figure 20: Unadjusted 5-year patient survival for intestine
transplants, by age, for 2003 and 2006.
at 5 years (Figure 20) was 51% for less than 1-year-olds,
53% for 1–5-year-olds, 69% for 6–10-year-olds and 61%
for 11–17-year-olds. These 5-year survival figures represent
outcomes for the cohort of patients transplanted several
years ago. It is to be hoped that the improvements seen
in 1-year survival will in time translate into improved 5-
year survival for the current cohort of intestine transplant
recipients. At the end of 2005, there were 265 pediatric
intestine recipients living with functioning transplants.
Immunosuppression
The data reported on induction drugs given are clearly in-
complete, as all the major intestine transplant programs
have been using induction regimens over the past few
years, employing either anti-lymphocyte preparations—
predominantly rabbit anti-thymocyte globulin but also alem-
tuzumab in older children—or IL-2R antagonists (anti-
CD25) basiliximab or daclizumab (30). However, the data
as available through the OPTN show no induction drugs
recorded in over 60% of pediatric cases in 2005.
Tacrolimus remains the mainstay of maintenance immuno-
suppression, with between 90% and 100% of recipients
receiving this drug prior to discharge between 1996 and
2005 (SRTR analysis, May 2006). In fact, 100% of recip-
ients with reported immunosuppression data during the
10-year period have received tacrolimus at some time be-
tween discharge and the end of their first year following
transplantation. Cyclosporine has not been used as a pri-
mary maintenance immunosuppressant since 2000, but
occasional recipients have received the drug later during
their first year after transplantation; usage fell from 19% in
1995 to 2% in 2004. The use of adjunctive anti-metabolite
medication as part of the primary immunosuppressive regi-
men has decreased from 67% (MMF 42% and azathioprine
25%) in 1996 to 14% in 2005, all of which was MMF. The
mTOR inhibitor sirolimus (Rapamune®, Wyeth, Philadel-
phia, PA, 1999) has been introduced during the last 10 years
and was first used in intestine recipients in 1999. In 2005,
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sirolimus was given to 11% of patients prior to discharge
and to 23% at some time up to 1 year following discharge.
In summary, the number of patients referred for and un-
dergoing intestine transplantation continues to increase.
Waiting list death rates remain much too high, particularly
for the smallest children who are at the greatest risk of
rapidly progressive liver disease. The differences in dis-
ease etiology, age and waiting list mortality between those
candidates requiring an intestine allograft alone or in com-
bination with a liver would suggest that it is time to con-
sider routinely analyzing these patients as two separate
groups, akin to the analysis for combined heart and lung
transplantation. Attempts are being considered that may
direct small donor livers (if suitable for use as a compos-
ite allograft with intestine) to the infants listed for both
organs rather than to children requiring a liver transplant
alone. Short-term survival following intestine transplanta-
tion is approaching that of other forms of solid organ trans-
plantation. Improvements in longer term outcomes are to
be expected, but assessing outcomes such as growth and
development will require data sets other than those col-
lected for SRTR analysis.
Heart Transplantation
Waiting list
Although the number of candidates on the heart waiting list
has decreased from 2436 in 1996 to 1334 in 2005, the num-
ber of pediatric candidates has not changed greatly, with
89 active on the waiting list at the end of 2005. While the
number of new pediatric registrants on the heart waiting
list has shown no consistent trend, the number of trans-
plants to pediatric recipients has increased, from 262 in
1996 to 313 in 2005; the number of pediatric deaths on the
waiting list has decreased slightly, with 80 deaths in 2005
(Figure 21). Infants <1 year and children 11–17 years have
accounted for the majority of new registrations in each of
the last 10 years (Figure 22). The smallest number of new
registrations was in the 6–10-year age group.
Transplantation and survival
Unadjusted 1-year patient survival for pediatric heart recip-
ients increases with increasing age, from 82% for children
less than 1 year old to 94% for those 11–17 years. In con-
trast, unadjusted 5-year patient survival decreased with in-
creasing age, from 75% among children less than 1 year to
72% among children 11–17 years (Figure 23). The preva-
lence of pediatric heart recipients alive with a functioning
graft followed the overall trend of all heart recipients, in-
creasing from 1225 at the end of 1996 to 2093 at the end
of 2004 (Figure 24).
For survivors of pediatric heart transplantation, the inher-
ent challenges of both short- and long-term care involve
prevention of graft vasculopathy (retransplantation may ul-
timately be required for lifetime care of this population in
Source: 2006 OPTN/SRTR Annual Report, Tables 11.3–11.4, and
15.3.
Figure 21: New pediatric heart waiting list registrants, deaths
on the waiting list and transplants, 1996–2005.
view of their younger age at the time of the primary trans-
plant); prevention and treatment of infection and malig-
nancy; and minimization of end-organ toxicities secondary
to chronic long-term complications of chronic immunosup-
pressive medications.
Renal dysfunction following cardiac transplantation:
One of the greatest concerns regarding the develop-
ment of end-organ toxicity is the decline in renal func-
tion seen late after heart transplantation with the current
calcineurin inhibitor-based immunosuppressive regimens
(31). Increasing numbers of children will require kidney
transplantation over the next decade following extra-renal
solid organ transplantation in childhood.
A recent study of pediatric heart recipients in the United
States from 1990 to 1999 who survived at least 1 year
after transplant found a 10-year actuarial risk of 4% for
Source: 2006 OPTN/SRTR Annual Report, Table 15.3.
Figure 22: New pediatric registrants on the heart waiting list,
by age, 1996–2005.
1350 American Journal of Transplantation 2007; 7 (Part 2): 1339–1358
Pediatric Transplantation, 1996–2005
Source: 2006 OPTN/SRTR Annual Report, Tables 11.10 and 11.14.
Figure 23: Unadjusted 1- and 5-year graft and patient survival
of heart transplants, by recipient age.
developing ESRD (defined as chronic dialysis and/or kid-
ney transplant) and a 10-year actuarial risk of 12% for
developing chronic renal insufficiency (CRI, defined as
creatinine >2.5 mg/dL, including those with ESRD). Those
who developed CRI had nine times the risk of death of pe-
diatric heart recipients without CRI (p < 0.0001) (31). An
SRTR analysis showed that during the 10-year period from
1996 to 2005, 55 pediatric heart transplant recipients were
placed on the kidney transplant waiting list and 53 pediatric
heart recipients underwent a subsequent kidney transplant
(SRTR analysis, May 2006).
Incompatible ABO donors for infant recipients: Chil-
dren in all age groups have a high risk of death while wait-
ing for a heart transplant, with the annual waiting list death
rate being higher in all pediatric age groups compared with
all adult candidates for most years. The highest death rate
is among infants aged less than 1 year, by greater than
a log scale difference (with a death rate of 2465 per 1000
Source: 2006 OPTN/SRTR Annual Report, Tables 11.16 and 12.16.
Figure 24: Prevalence of pediatric recipients living with a
functioning transplant at end of year, 1996–2004.
Source: SRTR Analysis, May 2006.
Figure 25: Immunosuppression use for induction for pediatric
recipients with heart transplants, 1996–2005.
patient-years at risk vs. 222–229 in children between 1 and
17 years and vs. 128–169 in candidates aged 18 years and
greater). A novel approach to dealing with this high death
rate was introduced by the team at Sick Children’s Hospi-
tal in Toronto (32). As a result of that pioneering work, a
policy was put in place in the United States to permit pedi-
atric candidates younger than 1 year who did not yet have
blood-type-specific antibodies to be listed for incompatible
hearts. Between January 1, 1999, and April 19, 2005, 16 pe-
diatric heart recipients under 1 year have been transplanted
in the United States with ABO-incompatible donors (SRTR
analysis, June 2006). The ages of the recipients ranged
from 0 to 7 months. Seven cases involved blood type A
donor into type O recipient, three cases were B into O,
three cases were B into A and three cases were AB into
O. All of the recipients were Status 1A prior to the trans-
plant. Five patients died following transplantation, four of
them within the first year, with an unadjusted posttrans-
plant survival of 75% at 1 year. Of the 16 recipients, only
one experienced graft failure in the absence of mortality.
There were 342 Status 1A patients less than 1 year of age
receiving transplants from blood-type compatible donors
during the same time period. Within that cohort, there were
67 deaths during the first year following transplantation,
with a resulting survival rate of 82%. Based on these ex-
tremely promising initial results, additional pediatric heart
transplant programs are developing blood type incompati-
ble programs. On September 29, 2006, the OPTN Board of
Directors approved a policy change that permits the upper
age range for the recipient of such a transplant to be ex-
tended to 2 years, assuming absence of blood type-specific
antibodies.
Immunosuppression
Induction immunosuppression: The use and composi-
tion of an induction regimen in pediatric heart transplant
recipients has continued to change over the last decade
(SRTR analysis, May 2006) (Figure 25). While the frequency
of use remains far below that seen currently in kidney
American Journal of Transplantation 2007; 7 (Part 2): 1339–1358 1351
Horslen et al.
Source: SRTR Analysis, May 2006.
Figure 26: Immunosuppression use for maintenance of pe-
diatric recipients with heart transplants prior to discharge,
1996–2005.
transplantation, there has been a gradual increase, espe-
cially in the past 6 years. The rationale for the choice of
agent, aside from its use at all, varies by center, and there
is a paucity of randomized studies to support these spe-
cific choices. During the past decade, the percentage of
pediatric heart recipients receiving an induction agent has
risen from a low of 25% in 1996 to a high of 53% in 2005.
In 1998, 73% of patients who received induction therapy
were given anti-thymocyte globulin, compared with only
20% in 2004. A more dramatic decline has been seen with
muromonab-CD3; 40% of induction patients received it in
1996 versus less than 2% in 2004. Practice patterns have
changed with the clinical availability of new agents, as con-
cerns have arisen regarding perceived increased risks of
vascular rejection (secondary to human-anti-murine anti-
body development), cytomegalovirus infection (CMV) and
posttransplant lymphoproliferative disorders (PTLD). Prac-
tice patterns have also shifted regarding use of corticos-
teroids for maintenance. The use of rabbit anti-thymocyte
globulin in pediatric heart transplantation increased from
0% in 1998 to 30% of all patients receiving induction in
2005. Similarly, the use of the anti-IL-2R antibodies da-
clizumab and basiliximab increased from 0% in 1997 to
39% in 2005. The year 2005 marks the first time alem-
tuzumab has been reported in heart recipients, although
usage was negligible.
The use and type of induction therapy also varied depend-
ing on whether the recipients were on steroids at the time
of discharge from the initial transplant event. Between
2001 and 2005, of the pediatric heart recipients who were
steroid-free at discharge, 41% received induction therapy;
rabbit anti-thymocyte globulin represented the single most
frequently used induction agent (58% of all induction use
in this group), followed by horse anti-thymocyte globu-
lin (31%). For patients who were maintained on steroids
(83% of all pediatric recipients) at discharge, use of induc-
tion therapy occurred in less than 40% of patients; for
those in that group who did receive induction, the anti-
IL-2R antibodies were the most commonly used agents
(44% of all induction use in this group) (SRTR analysis, May
2006).
Maintenance immunosuppression: Over the past
10 years, there has been a shift in the agents used for main-
tenance immunosuppressive therapy prior to discharge
(SRTR analysis, May 2006) (Figure 26). Cyclosporine-based
regimens have decreased dramatically, from 79% in 1996
to 32% in 2005. Conversely, use of tacrolimus-based reg-
imens has increased, from 16% in 1996 to 64% in 2005,
with 2005 being the first year that tacrolimus use exceeded
that of cyclosporine. Azathioprine demonstrated an even
greater decrease, from 77% in 1996 to 22% in 2005, while
MMF has become the anti-metabolite of choice, increasing
from 8% in 1996 to 66% in 2005. Sirolimus use was first
reported in 1999 and reached 8% in 2005. While corticos-
teroids are still employed for the majority of patients, use
has declined from a high of 94% in 2001 to a 10-year low
of 75% in 2005.
At the time of discharge in 2005, the single most common
regimen was the combination of tacrolimus and MMF in
46% of pediatric heart transplant recipients, followed by
cyclosporine and MMF in 20% of patients (SRTR analysis,
May 2006). The combination of cyclosporine and azathio-
prine was by far the most common regimen through the
1980s and mid-1990s (63% in 1996); it is now rarely em-
ployed (under 9% in 2005) (SRTR analysis, May 2006).
In the most recent cohort from 2004, by 1 year after trans-
plantation, use of tacrolimus-based regimens increased to
58%, while use of cyclosporine-based regimens decreased
to 38% (SRTR analysis, May 2006). Of the former, the com-
bination of tacrolimus, MMF and steroids remains the most
commonly used. Sirolimus as part of the regimen was used
in 6% of patients at 1 year following transplantation in the
2004 cohort.
The greatest change in maintenance immunosuppression
regimens over the first 3 years occurs between discharge
and 1 year, presumably in response to rejection, infection
and drug side effects (SRTR analysis, May 2006). Ongoing
‘regimen attrition’ occurs the subsequent years. The high-
est rate of conservation of the original discharge regimen
were seen in the tacrolimus/MMF and cyclosporine/MMF
groups, with 56% and 55% of patients, respectively, still
receiving those combinations 3 years after transplantation.
The highest rate of regimen change occurred in the cy-
closporine/azathioprine group, of which only 36% were still
receiving it at 3 years.
Steroid withdrawal: In the 2005 cohort, 25% of patients
were corticosteroid-free at discharge from the initial trans-
plant event. This represents a large (400%) increase in this
practice, compared with only 6% of patients in 2001 (SRTR
analysis, May 2006). In all of the pediatric heart recipients
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in the 2001–2005 cohort, 17% of recipients were steroid-
free at discharge. In that subgroup, 71% received some
form of induction therapy.
Anti-rejection treatment: There has been an overall
trend toward reduced use of all types of anti-rejection ther-
apy (SRTR analysis, May 2006). In 2004, 80 patients of a
total cohort of 291 received anti-rejection therapy (27%,
down from a 10-year high of 49% in 1998) during the first
year after transplant. This trend may reflect a true decrease
in acute rejection rates associated with the more modern
induction and maintenance regimens. Another contribut-
ing factor may be that more rejection episodes are be-
ing treated with only a change in maintenance regimen
agents; decreased rates of rejection may represent an
under-reporting of rejection episodes as measured by the
use of anti-rejection therapy.
The great majority of patients (89% to 98% over the
past 10 years) with reported anti-rejection therapy re-
ceived corticosteroids as treatment for the episode (SRTR
analysis, May 2006). In 2004, 16% of patients treated
for rejection received an anti-lymphocyte antibody prepa-
ration; the agent most commonly used was rabbit anti-
thymocyte globulin (61% of that group), followed by horse
anti-thymocyte globulin (23%). Of interest, 15% (2 of 13)
of the antibody-treated group received an anti-IL-2R anti-
body, despite little data supporting the use of this class for
the treatment of rejection.
Changes in pediatric heart allocation policy
Until recently, for candidates of all ages, hearts were al-
located locally before being offered out to the region. A
Status 2 candidate would receive a heart prior to a Sta-
tus 1A or 1B candidate waiting outside of the local OPO.
However, changes in the heart allocation algorithm have
adjusted the role of geography. Once offers to local adult
1A and 1B candidates are exhausted, the organ is offered
to Zone A (centers within 500 miles) Status 1A and 1B
candidates before being offered back to local centers for
Status 2 candidates.
The pediatric heart transplant community expressed con-
cerns that the new allocation algorithm would dispropor-
tionately jeopardize Status 2 pediatric candidates. While
adult Status 2 patients can be adequately managed medi-
cally and may not derive early benefit from transplantation,
similar data are not available for the pediatric population
due to the smaller numbers. For this reason, the OPTN
Thoracic Committee elected to continue with the local al-
location first policy for children.
Heart-Lung Transplantation
With an average of only seven pediatric heart-lung trans-
plants performed in the United States per year over the
past 10 years, it is difficult to make any definitive state-
ments regarding changing patterns. The challenges in pedi-
Source: 2006 OPTN/SRTR Annual Report, Tables 12.1a, 12.3–
12.4b.
Figure 27: Pediatric patients listed for lung transplant, dying
on the waiting list and transplanted, 1996–2005.
atric heart-lung transplantation seem to better reflect those
seen in isolated pediatric lung transplantation than those in
isolated heart transplantation. Since this procedure is per-
formed at so few centers, it is also likely that trends in
outcomes are related to the clinical practices and results
at the small subgroup of centers that perform a high vol-
ume of cases (i.e. three or more cases per year).
Waiting list
Heart-lung transplantation remains a relatively rare proce-
dure, with comparatively poor short- and long-term results.
During the past 10 years, the number of new pediatric
heart-lung registrants has decreased steadily, with only 13
new registrations in 2005. This has resulted in a gradual
decline in the number of patients on the waiting list. At the
end of 2005, only eight children were active on the heart-
lung waiting list. The reasons are likely multifactorial and
include use of bilateral lung transplantation as the proce-
dure of choice for children with parenchymal lung disease
and primary pulmonary hypertension. The relatively high
death rate on the waiting list and poor long-term survival
following transplantation may also discourage referral for
consideration of transplantation.
Transplantation and survival
Between 1996 and 2004, 67 pediatric heart-lung trans-
plants have been performed, with only 42 (63%) having
a functioning graft at the time of discharge and 35 (52%)
having a functioning graft 1 year following transplanta-
tion (SRTR analysis, May 2006). Only five such procedures




The numbers of pediatric lung candidates, deaths on the
waiting list and transplants per year have been steady over
the past decade, except for a large drop in the number of
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Source: 2006 OPTN/SRTR Annual Report, Table 12.10a.
Figure 28: Unadjusted graft survival at 3 and 5 years for de-
ceased donor lung transplant recipients, by age.
pediatric candidates over the past year, from 131 in 2004
to 77 in 2005 (Figure 27). While the total number of de-
ceased donor lung transplants has grown 78% over the
decade, from 791 in 1996 to 1407 in 2005, the number of
transplants in pediatric candidates showed no consistent
trend. Consequently, the proportion of lung transplants to
pediatric candidates has decreased: 4% of the recipients
were children in 2005 compared with 5% in 1996. In 2005,
53 pediatric candidates received lung transplants and 20
died waiting. The time until 25% of new registrants have
received a lung transplant has varied widely among pedi-
atric candidates over the past decade: between 17 and 156
days for registrants less than 1 year old, 39 and 279 days for
those 1–5 years, 54 and 883 days for children 6–10 years
and 110 and 783 days for adolescents aged 11–17 years.
Transplantation and survival
At 3 years following transplantation, children aged
6–10 years had the best unadjusted graft survival among
pediatric age groups at 73%, followed by 1–5-year-olds
and infants less than 1 year at 61% and finally 11–17-
year-olds at 56% (Figure 28). Unadjusted graft survival at
5 years showed a similar pattern: 56% among infants less
than 1 year, 68% among 6–10-year-olds, 38% among 1–5-
year-olds and 32% among 11–17-year-olds. At the end of
2004, 225 (4%) of the 5139 people alive with functioning
lung transplants had received their transplants as children
(Figure 24).
Immunosuppression
Induction immunosuppression: The use of an induc-
tion regimen in pediatric lung transplant recipients and the
types of agents used have changed over the last decade,
with a general increase starting in 1999 (SRTR analysis,
May 2006) (Figure 29). Center-specific practice patterns,
recipient comorbidities, concerns for infectious complica-
tions (particularly CMV and fungal infection) and the risk
of developing PTLD often have been cited as the primary
influences on the use of specific agents. During the past
decade, the percentage of pediatric lung recipients receiv-
ing an induction agent rose from 0% in 1997 to a decade
Source: SRTR Analysis, May 2006.
Figure 29: Immunosuppression use for induction for pediatric
recipients with lung transplants, 1996–2005.
high of 59% in 2005, in large part because of the avail-
ability of newer agents. Prior to 1999, anti-thymocyte glob-
ulin was the most commonly used induction agent. The
use of rabbit anti-thymocyte globulin increased from 0%
in 1999 to 17% in 2004, declining to 12% of all patients
receiving induction in 2005. The most dramatic and steady
increase is seen with the anti-IL-2R antibodies, daclizumab
and basiliximab; use grew from 0% in 1998 to 78% of all
pediatric patients receiving induction in 2005. Basiliximab is
currently the single most commonly used induction agent
in pediatric lung transplantation, accounting for 47% of all
induction used. Use of alemtuzumab is first reported in
2005, accounting for 9% (3 of 54) of all pediatric patients
receiving induction.
Maintenance immunosuppression: Over the past
10 years, there has been a shift in the agents used for main-
tenance immunosuppressive therapy prior to discharge
(SRTR analysis, May 2006) (Figure 30). Cyclosporine-based
regimens have decreased, from 78% in 1996 to 49% in
2005. Conversely, use of tacrolimus-based regimens has
Source: SRTR Analysis, May 2006.
Figure 30: Immunosuppression use for maintenance of pedi-
atric recipients with lung transplants prior to discharge, 1996–
2005.
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increased over the same period, from 12% in 1996 to 51%
in 2005. Azathioprine use has decreased even more, from
82% in 1996 to 31% in 2005, while MMF has increased
from less than 8% in 1996 to 61% in 2005. Sirolimus use
before discharge was first reported in 2000 (1 patient of
52), peaked at 4% (2 of 45) in 2002, and then declined back
to 0% from 2003 to the present, in response to safety is-
sues associated with impairment of bronchial anastomotic
healing. In contrast with recent trends among other solid
organs, corticosteroids are still used for maintenance prior
to discharge in virtually all patients (98% in 2005), as they
have been for the last 10 years.
At the time of discharge in 2005, the single most com-
mon regimen was the combination of tacrolimus, MMF
and steroids in 33% of pediatric recipients, followed by
cyclosporine, MMF and steroids in 28% of such patients
(SRTR analysis, May 2006). Cyclosporine combined with
azathioprine and steroids, by far the most common regi-
men through the 1980s and mid-1990s (65% in 1996), is
now used for maintenance prior to discharge in 20% of
patients.
In the most recent cohort from 2004, by 1 year after trans-
plantation use of tacrolimus-based regimens increased
to 64% while use of cyclosporine-based regimens de-
creased to 36% (SRTR analysis, May 2006). Of these
tacrolimus-based regimens, tacrolimus/MMF remains the
single most commonly used combination. Sirolimus as part
of the regimen was used in 5% of patients at 1 year fol-
lowing transplantation in the 2004 cohort.
Anti-rejection treatment: The trend has been toward
reduced use of all types of anti-rejection therapy (SRTR
analysis, May 2006). In 2004, 17 patients of a cohort of 57
received anti-rejection therapy (30%, down from a 10-year
high of 58% in 2000) during the first year after transplant.
As with heart transplantation, this trend may reflect a true
decrease in acute rejection rates associated with more
modern induction and maintenance regimens. Likewise,
it is conceivable that more rejection episodes are being
treated with only a change in the maintenance regimen; de-
creased rates of rejection may represent under-reporting of
rejection episodes as measured by the use of anti-rejection
therapy. Finally, use of fewer surveillance biopsies in many
lung transplant programs may yield a lower detection rate
and thus a falsely low reported rejection rate.
The great majority of patients (varying from 88% to 100%
over the past 10 years) with reported anti-rejection ther-
apy received corticosteroids as treatment for the episode
(SRTR analysis, May 2006). In 2003, 23% of patients
treated for rejection received an anti-lymphocyte antibody
preparation, the most common agent used being horse
anti-thymocyte globulin. Of interest, 15% (2 of 13) of the
antibody-treated group received an anti-IL-2R antibody, de-
spite little data supporting the use of this class of agents
for the treatment of rejection.
Source: 2006 OPTN/SRTR Annual Report, Tables 12.3–12.4b.
Figure 31: Ratio of lung waiting list deaths to transplants,
pediatric and adult, 1996–2005.
Recent changes in lung allocation
Waiting list mortality in the pediatric lung population histor-
ically has been high, as have waiting list deaths compared
with adults (Figure 31). A significant change in allocation
policy for deceased donor lungs was implemented in the
United States in May 2005. Formerly an allocation system
based primarily on waiting time, the new system now uses
the concepts of transplant benefit and medical urgency as
the principal mechanisms by which to distribute lungs to
transplant candidates aged 12 years and older (albeit with
geography still having a major effect); allocation policy did
not change for younger candidates.
The new allocation system is designed to maximize the
1-year survival benefit of lung transplantation by incorpo-
rating a prediction of the difference between measures of
waiting list survival and post-transplant survival for each
candidate. An additional goal is to minimize deaths on the
waiting list by balancing the benefit calculation and the de-
gree of medical urgency, as embodied in the waiting list
survival measure. Four main categories of diagnosis were
found to be strongly associated with waiting list and post-
transplant mortality. These include Group A: obstructive
lung diseases, typified by chronic obstructive pulmonary
disease; Group B: pulmonary vascular diseases, principally
primary pulmonary hypertension; Group C: cystic fibrosis
and immunodeficiency disorders; and Group D: restrictive
lung diseases, mainly idiopathic pulmonary fibrosis. About
20% of candidates and recipients have diagnoses other
than the four mentioned, and these were assigned into
one of the four groups using a combination of pathophysi-
ologic similarity and comparable waiting list mortality risk.
A number of other factors were significant in these mortal-
ity models, some of which varied substantially by diagno-
sis group, either in magnitude or degree of importance. In
these cases, appropriate interaction terms were included
to allow the impact of a risk factor to differ across diagnosis
group.
Group E is reserved for patients under 12 years, irrespec-
tive of diagnosis. Analyses of pediatric candidates and re-
American Journal of Transplantation 2007; 7 (Part 2): 1339–1358 1355
Horslen et al.
cipients demonstrated that adolescent mortality risk was
very similar to that for adults. In contrast, children under 12
years represent a heterogeneous group of diagnoses, of-
ten with unpredictable natural histories. Predictive factors
for mortality in younger children—for which the numbers
are much smaller, thus making modeling more difficult—
have yet to be adequately determined. Therefore, alloca-
tion of donor lungs for these patients continues to be based
on waiting time. For candidates 12 years and older, pa-
tients are ranked by an allocation score that is calculated
as the difference between the transplant benefit mea-
sure (posttransplant survival measure minus the waiting
list urgency measure) and the waiting list (urgency) mea-
sure. Mathematically, the value of this raw allocation score
can range from −730 to +365. To facilitate understand-
ing, the raw allocation score is normalized to a scale from
0 to 100 and is referred to as the lung allocation score
(LAS).
In an attempt to improve access to lungs for pediatric and
adolescent recipients, a preferential allocation of pediatric
and adolescent donor lungs to an age-matched recipient
cohort has been incorporated as part of the new system.
Lungs from donors aged less than 12 years are allocated
to candidates aged less than 12 years first (based on candi-
date waiting time), then to candidates between 12 and 17
years (based on the LAS) and then last to candidates older
than 18 years (again based on LAS). Lungs from donors
aged 12–17 years are allocated to candidates between 12
and 17 years (based on LAS), then to candidates less than
12 years (based on waiting time) and then last to candi-
dates older than 18 years (again based on LAS). Finally,
lungs from donors older than 18 years are allocated to all
candidates older than 12 years (based on LAS) before being
offered to candidates less than 12 years (based on waiting
time).
The new allocation system was implemented on May 4,
2005, and preliminary data have been recently analyzed
(SRTR analysis, April 2006). In the initial 11 months, the
number of active candidates older than 12 years with a
nonzero score has decreased from 1269 to 874, a decline
of over 30%, while the number of candidates younger than
12 years has remained constant. This alone is noteworthy;
prior to the implementation of the LAS, the size of the lung
waiting list had increased every year since its inception.
As of March 29, 2006, the median LAS was 33.6. There is
substantial overlap between the distributions of the LAS
(10th to 90th percentiles) across the four major diagnosis
groups. The median LAS is slightly higher for Groups C
and D compared with Groups A and B. The distribution of
diagnosis groups among transplant recipients has shifted
substantially, as has the position on the match run since
the LAS was implemented. Prior to May 2005, almost half
of the transplants were in group A and a third in group D.
In the 6 months following institution of the LAS, the dis-
tribution reversed, with now almost half in group D and a
third in group A. The distributions for groups B and C have
not substantially changed in the first 6 months. Prior to
LAS implementation, the transplant recipient was on aver-
age (median) 11th on the match run list for the organ with
a 90th percentile of 143. Subsequent to implementation
of the LAS, the median position on the list (for the first
9 months after implementation) is 5th with a 90th per-
centile of only 61. This translates into a considerable time
savings for an OPO in lung placement.
Of great importance to the pediatric lung transplant com-
munity is the change that has occurred in the recipient and
donor ages. Although the total number of lung transplants
involving pediatric donors aged 0–11 years is essentially
unchanged during the two time periods (27 from May 4,
2004, to January 31, 2005, and 28 from May 4, 2005, to
January 31, 2006), more of these young donor lungs are
being directed toward adolescent recipients than under the
old system (32% vs. 7%, respectively) instead of going to
recipients older than 18 years. This is a goal of the LAS
system, and the additional priority for pediatric organs go-
ing to pediatric recipients is clearly working. The allocation
of adolescent donor organs (donors aged 12–17 years) has
also shifted toward adolescent recipients and away from
adults, although not to as great a degree as for the young
pediatric donor organs.
With relatively small numbers and little time for follow-up,
it is too early to make any definitive conclusions regarding
the effect of the LAS on death rates on the waiting list or
in the first year after transplantation. Preliminary favorable
results for death rates per 100 patient-years on the waiting
list for candidates 12 years and older show 14.1 deaths/100
patient-years (May 4, 2004, to December 31, 2004) versus
12.3 deaths/100 patient-years (May 4, 2005, to December
31, 2005) with all diagnostic groups combined. Of partic-
ular interest to the pediatric lung transplant community is
the change in Group C (consisting predominantly of cys-
tic fibrosis patients) from 16.1 deaths/100 patient-years to
12.0 deaths/100 patient-years. There were no changes in
the death rate seen for group B (which includes the pul-
monary hypertension cohort).
A high degree of caution needs to be exercised in mak-
ing conclusions when comparing results between eras or
diagnosis groups, given possible differences in patient pop-
ulations. The profile of patients added to the waiting list af-
ter the LAS was implemented appears to differ from that
added in the immediate prior year. For candidates younger
than 12 years, an even higher degree of caution needs
to be exercised in making any conclusions. In addition to
changing patient profiles, there are very small numbers
of patients and deaths. With that taken into account, pre-
liminary results show a drop from 10.6 to 6.9 deaths/100
patient-years for all diagnostic groups combined. While the
individual risk of death on the waiting list is expected to
decrease dramatically under the LAS system, we may in
fact observe a higher death rate among listed patients.
This is possible because the active waiting list population
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has shifted from less urgent patients interested in accru-
ing waiting time to patients in immediate need of an organ.
Also, urgent patients who, under the LAS system, might
survive long enough to be offered an organ are joining the
waiting list under the new system when they would not
likely have done so with a system based on waiting time.
Posttransplant outcomes also may reflect the more urgent
patients with high benefit being selected for transplanta-
tion. Evaluating the impact of the LAS on mortality will
require careful thought.
The LAS system is a work in progress. Central to the new
algorithm is a plan to regularly review the predictive mod-
els for waiting list and posttransplant mortality and to up-
date them as needed. It is anticipated that serial clinical
data will be useful in identifying new factors that should be
incorporated into the distribution algorithm and that serially
collected patient data may affect the importance of fac-
tors identified as significant in the analyses. At least every
6 months, analyses will be performed to identify factors
and to possibly modify their hazard ratios in the algorithm.
Thus, as patients are transplanted and removed from the
list and new patients are added, risk is assessed using
the most recent cohort of patients. Equally important is a
provision for updating candidate data while on the waiting
list. The current LAS system is based on data obtained at
the time of waiting list placement and at transplant, as se-
rial data were not available during the LAS development
phase. It is anticipated that incorporating more current in-
formation into the algorithm will be a major enhancement.
The important predictors of mortality are likely to change
over time in concert with progression of the patient’s un-
derlying pulmonary disorder. The current LAS system does
not address the issues of geographic disparities in access
to lungs, as there is still a strong effect of prioritizing lungs
locally rather than via a zonal or regional sharing mecha-
nism/algorithm. It is hoped that this will be incorporated
with further modifications to the lung allocation system
if ‘local first’ is eliminated, similar to the newly approved
heart allocation zonal sharing proposal.
Summary
In distinction from the steady increase in pediatric candi-
dates each year through the 1990s, the trend since 2001
has been for relative stability in the number of pediatric
waiting list registrants and transplant recipients across the
organ groups, with the exception of patients needing intes-
tine transplantation. Improving outcomes in terms of graft
and patient survival continue to be seen, in most cases
exceeding that seen in adult transplant recipients. With
improved survival, focus has increasingly shifted to long-
term outcomes other than survival alone, such as growth,
development and renal function in nonrenal transplant re-
cipients. Trends in immunosuppressive therapy across all
organs show a move toward increased use of induction
agents, especially rabbit anti-thymocyte globulin and IL-2R
antagonists. Tacrolimus, with or without MMF, is most fre-
quently employed for maintenance immunotherapy. Also,
a gradual advance of steroid-free protocols is evident for
all organs, except lung.
Allocation systems continue to undergo modification, of-
ten radically as in the case of the LAS. While allocation of
organs to children is often secondary to the vastly larger
adult waiting lists, all concerned with pediatric organ trans-
plant patients, not least the OPTN Pediatric Committee,
endeavor to maintain and improve access of children with
end-stage organ failure to lifesaving transplantation. De-
spite improvements, waiting list and postoperative mor-
tality rates are still far from negligible. Further progress is
needed and expected.
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